SARC028 was a multicenter, two-cohort, single-arm, open-label phase II study evaluating the anti-PD-1 antibody, pembrolizumab, in 40 patients with advanced soft tissue sarcoma[13]. Here, RPL17 is linked to soft tissue sarcoma.